Table 1. BC patients with detectable ESO Ab and/or ESO expression and characteristics of the corresponding tumors.

Patient	ESO Ab	ESO exp*	ER†	PR†	HER2‡	Age§	SBR∥	Histological type	Other tumors	Survival§§	Relapse	Family history∫∫
NB1/78	+	na	−	−	−	26	III	IDC††	-	D	Liver	+
NB1/11	+	+	−	−	+	61	III	IDC	Meningioma	A	-	+
NB5/35	+	+	−	−	nd	52	up**	up	-	A	-	−
NB1/27	+	+	−	−	−	59	III	IDC	-	A	-	−
NB15/55	+	na	−	−	−	48	up	up	Cervical	A	-	+
NB1/41	+	+	−	−	−	61	III	IDC	-	A	Skin, LN	+
NB1/4	+	+	−	−	−	57	III	IDC	-	A	-	−
NB14/73	+	na	−	−	+	68	III	IDC	-	A	-	−
NB1/17	+	+	−	−	−	37	III	IDC	-	D	LN	+
NB7/6	+	+	−	−	+	65	III	IDC	Spinocellular	A	-	−
NB14/56	+	+	−	−	−	66	III	MBC‡‡	-	A	-	−
NB2/67	+	−	+	−	−	71	I	IDC	Melanoma	A	-	−
NB1/8	−	+	−	−	−	65	II	IDC	-	A	-	+
NB1/13	−	+	−	−	−	48	III	IDC	-	A	-	−
NB1/15	−	+	−	−	−	56	II	IDC	-	D	Pleural, skin, LN	+
NB1/26	−	+	−	−	−	65	III	IDC	-	A	-	−
NB1/37	−	+	−	−	+	83	III	ILC∫	-	A	-	−
NB1/38	−	+	−	−	−	55	III	Basal-like	-	A	-	−
NB1/47	−	+	−	−	−	58	III	IDC	-	A	-	−
NB1/80	−	+	−	−	−	74	III	IDC	-	D	Skin	−
NB1/85	−	+	−	−	−	42	III	MBC	-	A	-	+
NB14/78	−	+	−	−	−	62	III	IDC	-	A	-	−

^*ESO mRNA expression in frozen tumor specimens was assessed by RT-PCR. na, not available.

^†ER and PR expression was assessed by IHC staining of paraffin-embedded tumor specimens.

^‡HER2 was assessed by IHC staining in paraffin-embedded tumor specimens and gene amplification was confirmed by FISH analysis. nd, not done.

^§Age at diagnosis.

^∥SBR, Scarff-Bloom-Richardson tumor grade.

^**Lymph node metastasis with unknown primary (up).

^††IDC, invasive ductal carcinoma.

^‡‡MBC, medullary breast cancer.

^∫ILC, invasive lobular carcinoma.

^§§D, dead; A, alive.

^∫∫Known family history of breast cancer.